WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406657

CAS#: 218156-96-8

Description: SRPIN340 is a selective serine arginine protein kinase (SRPK) 1 inhibitor with Ki = 0.89 μM. SRPK1 is a common binding partner of the E1^E4 protein of diverse human papillomavirus types. SRPK1 selective inhibitors could be a potentially novel topical (eye drop) therapeutic for wet AMD.

Chemical Structure

CAS# 218156-96-8

Theoretical Analysis

MedKoo Cat#: 406657
Name: SRPIN340
CAS#: 218156-96-8
Chemical Formula: C18H18F3N3O
Exact Mass: 349.1402
Molecular Weight: 349.35
Elemental Analysis: C, 61.88; H, 5.19; F, 16.31; N, 12.03; O, 4.58

Size Price Shipping out time Quantity
10mg USD 150 Same day
25mg USD 250 Same day
50mg USD 350 Same day
100mg USD 450 Same day
200mg USD 750 Same day
500mg USD 1450 Same day
1g USD 2250 Same day
2g USD 3850 Same day
5g USD 5950 Same day
Inquire bulk and customized quantity

Pricing updated 2021-03-05. Prices are subject to change without notice.

SRPIN340, purity > 98%, is in stock. The same day shipping out after order is received.

Synonym: SRPIN340; SRPIN-340; SRPIN 340.

IUPAC/Chemical Name: N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)isonicotinamide


InChi Code: InChI=1S/C18H18F3N3O/c19-18(20,21)14-4-5-16(24-10-2-1-3-11-24)15(12-14)23-17(25)13-6-8-22-9-7-13/h4-9,12H,1-3,10-11H2,(H,23,25)


Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Preparing Stock Solutions

The following data is based on the product molecular weight 349.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Gammons MV, Lucas R, Dean R, Coupland SE, Oltean S, Bates DO. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br J Cancer. 2014 Jul 29;111(3):477-85. doi: 10.1038/bjc.2014.342. Epub 2014 Jul 10. PubMed PMID: 25010863; PubMed Central PMCID: PMC4119992.

2: Gammons MV, Dick AD, Harper SJ, Bates DO. SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2013 Aug 27;54(8):5797-806. doi: 10.1167/iovs.13-11634. PubMed PMID: 23761094.

3: Dong Z, Noda K, Kanda A, Fukuhara J, Ando R, Murata M, Saito W, Hagiwara M, Ishida S. Specific inhibition of serine/arginine-rich protein kinase attenuates choroidal neovascularization. Mol Vis. 2013;19:536-43. Epub 2013 Mar 5. PubMed PMID: 23559848; PubMed Central PMCID: PMC3611948.

4: Ogawa Y, Hagiwara M. Challenges to congenital genetic disorders with "RNA-targeting" chemical compounds. Pharmacol Ther. 2012 Jun;134(3):298-305. doi: 10.1016/j.pharmthera.2012.02.001. Epub 2012 Feb 9. Review. PubMed PMID: 22342810.

5: Karakama Y, Sakamoto N, Itsui Y, Nakagawa M, Tasaka-Fujita M, Nishimura-Sakurai Y, Kakinuma S, Oooka M, Azuma S, Tsuchiya K, Onogi H, Hagiwara M, Watanabe M. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. Antimicrob Agents Chemother. 2010 Aug;54(8):3179-86. doi: 10.1128/AAC.00113-10. Epub 2010 May 24. PubMed PMID: 20498328; PubMed Central PMCID: PMC2916360.

6: Fukuhara T, Hosoya T, Shimizu S, Sumi K, Oshiro T, Yoshinaka Y, Suzuki M, Yamamoto N, Herzenberg LA, Herzenberg LA, Hagiwara M. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11329-33. Epub 2006 Jul 13. PubMed PMID: 16840555; PubMed Central PMCID: PMC1544086.

Additional Information